The Institutional Biosafety Committee (IBC) of the University of Connecticut is committed to promoting research and instructional activities by ensuring that all experiments using biological materials are conducted in full compliance with the current editions of NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) issued by the National Institutes of Health (NIH) and Biosafety in Microbiological and Biomedical Laboratories (BMBL) issued by the Centers for Disease Control and Prevention (CDC). With the cooperative effort of Principal Investigators, the IBC will assess the health and safety impacts of the use of biohazards and promote the safe use of such materials by enhancing investigators’ understanding of federal, state, and local regulations related to the use of biological materials.
The Institutional Biosafety Committee (IBC) was established to review research and teaching activities that involve biological materials including but not limited to: recombinant or synthetic nucleic acid molecules (rsNA), biological agents and toxins, bacteria and their phages and plasmids, viruses, fungi, mycoplasmas, prions, and parasites; human and non-human primate tissues, body fluids, blood, blood byproducts, and cell lines, animal remains and insects that may harbor zoonotic pathogens.
The purpose of the review process is to ensure that University activities comply with government regulations, and provide appropriate safeguards for human health and the environment.
The IBC oversight process is based on the requirement that all biological research that falls within the committee’s purview is registered, reviewed, and approved on a recurring basis at meetings of the IBC. The IBC review and approval process is based on the completion and submission of the IBC Registration forms to the IBC Office.
The IBC provides guidance on research safety issues as described in the NIH Guidelines (Section IV-B-2-b). For example, the IBC will assess facilities, incidents, procedures, practices, training and expertise of personnel involved with rsNA research. The IBC will ensure compliance with all necessary health surveillance, data reporting, and adverse event reporting requirements. The IBC also works to ensure compliance with other relevant federal and state regulations.